Finoriq research workspace
Benitec Biopharma Inc. (BNTC) Company Overview
Review a simplified SEC filing overview, TradingView market widgets, and reported line items for Benitec Biopharma Inc. (BNTC).
Company Snapshot
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.
- Company
- Benitec Biopharma Inc. (BNTC)
- Ticker
- BNTC
- Market Cap
- $410.9M
- Latest Price
- $11.96
- Industry
- Biotech & Pharma
Benitec Biopharma Inc. (BNTC) Current Valuation Metrics
Static valuation preview for Benitec Biopharma Inc. (BNTC). Market data retrieved 2026-07-09. Filing currency USD.
| Metric | Value | Source |
|---|---|---|
| Earnings YieldLatest TTM net income divided by market cap. | -8.4% | Net Income | TTM Q2 2026 |
| Operating Cash Flow YieldLatest TTM operating cash flow divided by market cap. | -4.0% | Operating Cash Flow | TTM Q2 2026 |
| Price / BookMarket cap divided by stockholders' equity. | 2.49x | Stockholders' Equity | Q2 2026 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.